TNF and sTNFR1/2 plasma levels in ALS patients

Cereda, Cristina; Baiocchi, Chiara; Bongioanni, Paolo; Cova, Emanuela; Guareschi, Stefania; Metelli, Maria Rita; Rossi, Bruno; Sbalsi, Ilaria; Cuccia, M.; Ceroni, Mauro

doi:10.1016/j.jneuroim.2007.10.028

Cited by 84 publications

(68 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Upregulation of TNFα and TNF receptors is observed in parallel with the appearance of symptoms in SOD1 mice [23,24] and increased levels of TNFα are found in plasma of ALS patients [25]. However, genetic ablation of TNFα has no beneficial effect on survival, motor axon degeneration or gliosis in either of two different lines of mutant SOD1 mice [26•].…”

Section: Involvement Of Death Receptors In Disease Mechanism and Thermentioning

confidence: 99%

Signaling by death receptors in the nervous system

Haase

Pettmann

Raoul

et al. 2008

Current Opinion in Neurobiology

View full text Add to dashboard Cite

SummaryCell death plays an important role both in shaping the developing nervous system and in neurological disease and traumatic injury. In spite of their name, death receptors can trigger either cell death or survival and growth. Recent studies implicate five death receptors -Fas/CD95, TNFR1 (tumor necrosis factor receptor-1), p75 NTR (p75 neurotrophin receptor), DR4 and DR5 (death receptors-4 and -5) -in different aspects of neural development or degeneration. Their roles may be neuroprotective in models of Parkinson's disease, or pro-apoptotic in ALS and stroke. Such different outcomes likely reflect the diversity of transcriptional and post-translational signaling pathways downstream of death receptors in neurons and glia.

show abstract

Section: Involvement Of Death Receptors In Disease Mechanism and Thermentioning

confidence: 99%

Signaling by death receptors in the nervous system

Haase

Pettmann

Raoul

et al. 2008

Current Opinion in Neurobiology

View full text Add to dashboard Cite

show abstract

“…We hypothesised that in the majority of ALS patients TNF- plasma concentration has already reached its peak at disease onset, remains high during all disease duration and starts to decrease at the end of the disease. This finding suggests that TNF- pathway could be activated in the first stage of the disease and it decreases its effect with the progression of the disease (Cereda et al, 2008).…”

Section: Tnf- Level In Peripheral Blood Of Als Patientsmentioning

confidence: 82%

“…In all plasma patients soluble forms of the TNF- and its receptors are found increased already at disease onset and remain over the normal range during the disease progression time (Cereda et al, 2008). In addition TNF- amounts have been found higher in sera from sporadic ALS patients but no correlation was found with the clinical criteria (Poloni et al, 2000;Cereda et al, 2008). TNF- role in neurodegeneration will be further highlight in the next paragraph.…”

Section: Cytokinesmentioning

confidence: 92%

“…Plasma concentration of TNF-, TNF-R1 and TNF-R2 and their time course during disease progression were studied in ALS patients in order to assess the TNF- system implication in ALS pathogenesis. In all plasma patients soluble forms of the TNF- and its receptors are found increased already at disease onset and remain over the normal range during the disease progression time (Cereda et al, 2008). In addition TNF- amounts have been found higher in sera from sporadic ALS patients but no correlation was found with the clinical criteria (Poloni et al, 2000;Cereda et al, 2008).…”

Section: Cytokinesmentioning

confidence: 96%

“…Even after dividing the patients in two subgroups, with high and low TNF- levels, they did not find any difference in terms of clinical parameters of the disease (Poloni et al, 2000). Our research group analyzed the possible implication of TNF- pathway in ALS pathogenesis (Cereda et al, 2008). We assayed both the levels of TNF- and its soluble receptors in plasma from ALS patients overtime during disease progression.…”

Section: Tnf- Level In Peripheral Blood Of Als Patientsmentioning

confidence: 99%

See 2 more Smart Citations

The Role of TNF-Alpha in ALS: New Hypotheses for Future Therapeutic Approaches

Cereda¹,

Gagliardi²,

Cova³

et al. 2012

Amyotrophic Lateral Sclerosis

Self Cite

View full text Add to dashboard Cite

Characterization of Gene Expression Phenotype in Amyotrophic Lateral Sclerosis Monocytes

et al. 2017

View full text Add to dashboard Cite

IMPORTANCE Amyotrophic lateral sclerosis (ALS) is a common adult-onset neurodegenerative disease characterized by selective loss of upper and lower motor neurons. Patients with ALS have persistent peripheral and central inflammatory responses including abnormally functioning T cells and activated microglia. However, much less is known about the inflammatory gene profile of circulating innate immune monocytes in these patients.OBJECTIVE To characterize the transcriptomics of peripheral monocytes in patients with ALS. DESIGN, SETTING, AND PARTICIPANTS Monocytes were isolated from peripheral blood of 43 patients with ALS and 22 healthy control individuals. Total RNA was extracted from the monocytes and subjected to deep RNA sequencing, and these results were validated by quantitative reverse transcription polymerase chain reaction. MAIN OUTCOMES AND MEASURESThe differential expressed gene signatures of these monocytes were identified using unbiased RNA sequencing strategy for gene expression profiling. RESULTSThe demographics between the patients with ALS (mean [SD] age, 58.8 [1.57] years; 55.8% were men and 44.2% were women; 90.7% were white, 4.65% were Hispanic, 2.33% were black, and 2.33% were Asian) and control individuals were similar (mean [SD] age, 57.6 [2.15] years; 50.0% were men and 50.0% were women; 90.9% were white, none were Hispanic, none were black, and 9.09% were Asian). RNA sequencing data from negative selected monocytes revealed 233 differential expressed genes in ALS monocytes compared with healthy control monocytes. Notably, ALS monocytes demonstrated a unique inflammation-related gene expression profile, the most prominent of which, including IL1B, IL8, FOSB, CXCL1, and CXCL2, were confirmed by quantitative reverse transcription polymerase chain reaction (IL8, mean [SE], 1.

show abstract

TNF and sTNFR1/2 plasma levels in ALS patients

Cited by 84 publications

References 47 publications

Signaling by death receptors in the nervous system

Signaling by death receptors in the nervous system

The Role of TNF-Alpha in ALS: New Hypotheses for Future Therapeutic Approaches

Characterization of Gene Expression Phenotype in Amyotrophic Lateral Sclerosis Monocytes

Contact Info

Product

Resources

About